Oncolytics Biotech (ONCY) Set to Announce Quarterly Earnings on Thursday

Oncolytics Biotech (NASDAQ:ONCY) will be posting its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Oncolytics Biotech to post earnings of ($0.09) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncolytics Biotech Price Performance

Shares of ONCY opened at $1.12 on Thursday. The business’s 50 day simple moving average is $1.06 and its 200-day simple moving average is $1.26. Oncolytics Biotech has a 1 year low of $0.88 and a 1 year high of $3.39. The stock has a market capitalization of $84.47 million, a price-to-earnings ratio of -3.70 and a beta of 1.93.

Analysts Set New Price Targets

Several research firms have commented on ONCY. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oncolytics Biotech in a research report on Friday, January 12th. Raymond James began coverage on Oncolytics Biotech in a report on Thursday, April 4th. They issued an “outperform” rating and a $3.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a research note on Wednesday, February 14th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.